Sorafenib When You Are Older — or Have Other Illnesses

Age alone does not determine the starting dose. NCCN guidance does not recommend a routine reduction based on age. What matters is how your liver, kidneys and cardiovascular system are functioning. If those are in an acceptable range, you start on the same dose as a younger patient. If organ function is reduced, your team may begin differently or adjust based on how you tolerate the first few weeks.

It depends on how severe the cirrhosis is. Doctors use the Child-Pugh score to grade liver function. Child-Pugh A, which means relatively preserved liver function, generally allows sorafenib at the standard starting dose with close monitoring. Child-Pugh B requires a careful weighing of risk and benefit. Child-Pugh C, which represents severe liver failure, is a situation where sorafenib is not recommended because the liver cannot process the drug safely. Your team will check liver function before you start and at regular intervals during treatment.

It requires more attention, but it is manageable. Sorafenib raises blood pressure in a proportion of patients. If yours is already elevated before you start, your team will aim to bring it under control first — adding or adjusting blood pressure medicines if needed. During treatment, blood pressure is checked at each visit. Persistent or severe high blood pressure on sorafenib is addressed with medicines rather than automatically stopping the drug.

Mild to moderate kidney impairment does not usually require a dose change. Sorafenib is primarily broken down and removed by the liver and gut, not the kidneys, so reduced kidney function has less impact on drug levels than liver disease does. Your team will still monitor kidney function during treatment and check for protein in your urine, which can appear as a side effect of sorafenib regardless of your starting kidney health. If you have severe kidney impairment, your oncologist will discuss what the evidence supports for your situation.

Yes, and for many patients this is necessary. Because sorafenib raises blood pressure in a proportion of patients, some people start a blood pressure medicine specifically because of their treatment. If you are already on one, your team will continue it and may adjust the dose during sorafenib. Some blood pressure medicines interact with sorafenib more than others, so tell your oncologist exactly which medicines you take and at what dose.

It requires closer monitoring rather than ruling sorafenib out. Sorafenib interacts with warfarin and can raise your INR — the measure of how quickly your blood clots — which increases bleeding risk if not managed. If you take warfarin, your team will check your INR more frequently, particularly in the first weeks of treatment. Tell both your oncologist and your GP so both can coordinate monitoring. Do not stop warfarin without advice from your team.

It can be more uncomfortable. Hand-foot skin reaction — redness, soreness and thickening of the skin on the palms and soles — is one of the more common side effects of sorafenib. Some evidence suggests older patients or those with reduced circulation may find it more troublesome. Starting to moisturise hands and feet from the first day of treatment helps, as does wearing well-padded footwear. Tell your team at the first sign rather than waiting, because early management prevents it from becoming severe enough to affect how you walk or function day to day.

More frequently than for a younger patient with no other health problems, especially in the first two to three months. Your team will typically check blood pressure, liver function tests, kidney function and a full blood count at these visits, alongside an assessment of how you are tolerating the drug. If everything stays stable, the interval between checks may gradually extend. If you notice a new symptom between appointments, contact your team rather than waiting for the next scheduled visit.